News | May 29, 2023
Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
The facility will produce 150 million vaccine doses per year
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The facility is spread across 215000 sq. feet and provides super-speciality care
Subscribe To Our Newsletter & Stay Updated
